Vivet Therapeutics
Clinical-stage gene therapy developer for rare inherited liver metabolic diseases, based in Paris
Highlights
- New on EvolcAdded 2026-11-02
About Vivet Therapeutics
Vivet Therapeutics is a clinical-stage biotechnology company developing liver-directed rAAV gene therapies for rare inherited metabolic diseases. Its pipeline builds on recombinant AAV technologies licensed exclusively from FIMA, a not-for-profit foundation at CIMA, University of Navarra in Pamplona, Spain.
The lead asset, VTX-PID, is an IgG-degrading enzyme designed to remove pre-existing neutralizing antibodies that block AAV-based gene therapy. Other programs include VTX-806 for cerebrotendinous xanthomatosis, VTX-802 for progressive familial intrahepatic cholestasis type 2, now under license to Amets Biotechnology, and VTX-801 for Wilson's disease. Lexeo Therapeutics has entered into an option agreement for an exclusive license to VTX-PID.
Vivet was founded in 2016 and is headquartered in Paris, France. Its leadership includes CEO and co-founder Jean-Philippe Combal. The company is backed by investors including Novartis Venture Fund, Roche Venture Fund, HealthCap, Pfizer, Columbus Venture Partners, Ysios Capital, Kurma Partners and Eurazeo. Its careers page lists no open positions.
Product: Liver-directed rAAV gene therapies (VTX-PID, VTX-806, VTX-802, VTX-801) for rare inherited metabolic diseases.
Jobs at Vivet Therapeutics
Leadership
- Gloria Gonzalez-Aseguinolaza · Co-Founder & Strategic AdvisorSource: company website
- Jean-Philippe Combal · Chairman, Co-founder & CEOSource: company website
More biotech & pharma companies
Whitelab Genomics
AI and computational biology tools for biotech and pharmaceutical teams developing genomic medicinesNew on EvolcXenothera
Develops glyco-humanized antibody treatments for patients with a range of therapeutic needsNew on EvolcZymoptiq
Enzyme activity testing products and analytical services for industrial and research customersNew on Evolc4P-Pharma
Clinical-stage biotech developing drug candidates for serious diseases with unmet medical needsNew on EvolcAb Science
Develops pharmaceutical compounds for clinical programs in neurology, inflammatory diseases, oncology and viral diseasesNew on EvolcAbbelight
Super-resolution microscopy platform, sample-prep reagents and analysis software for biology researchers and biotech labsNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- ElementorHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- Contact Form 7High confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- Google reCAPTCHAHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- ApacheHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.